Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05610800 · ClinicalTrials.gov registry record · Phase 2
Exenatide for Smoking Cessation and Prevention of Weight Gain
A Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT05610800 is a Phase 2 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 140 participants.
The verdict
NCT05610800, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if exenatide improves end-of-treatment smoking abstinence rates and to determine if exenatide mitigates post-cessation weight gain.
Interventions
- DRUG Placebo
- BEHAVIORAL Smoking Cessation Counseling
- DRUG Nicotine patch
- DRUG Exenatide 2 milligram (mg) Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2022-12-07 |
| Est. Completion | 2026-03-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05610800
The ClinicalTrials.gov registry entry for NCT05610800 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT05610800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05610800 about?
NCT05610800 is a clinical study titled "Exenatide for Smoking Cessation and Prevention of Weight Gain". The purpose of this study is to determine if exenatide improves end-of-treatment smoking abstinence rates and to determine if exenatide mitigates post-cessation weight gain.
What is the current status of trial NCT05610800?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2022-12-07. Estimated completion is 2026-03-10.
What interventions are being tested in trial NCT05610800?
The interventions under investigation include: Placebo (DRUG), Smoking Cessation Counseling (BEHAVIORAL), Nicotine patch (DRUG), Exenatide 2 milligram (mg) Injection (DRUG).
Who is sponsoring clinical trial NCT05610800?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.